Wellbutrin and hair loss is a concern raised by patients taking bupropion, the active ingredient in Wellbutrin — a brand not licensed in the UK, where bupropion is available only as Zyban for smoking cessation. Alopecia is listed as an adverse effect in the UK Summary of Product Characteristics (SmPC) for Zyban, though it remains uncommon and is not an inevitable consequence of treatment. Understanding the evidence, potential mechanisms, and practical steps to take if hair shedding occurs can help patients and clinicians make informed, balanced decisions about bupropion use.

Can Bupropion Cause Hair Loss?

Alopecia is listed as an adverse effect in the UK Zyban SmPC; if bupropion contributes to hair loss, it most likely manifests as reversible telogen effluvium, typically appearing two to four months after starting treatment.

Experiencing these side effects? Our pharmacists can help you navigate them →

Wellbutrin is a brand name for bupropion that is not licensed in the UK. In the UK, bupropion is licensed solely as Zyban for smoking cessation. Its use as an antidepressant is off-label and unlicensed in the UK, and would typically be initiated and overseen by a specialist. Patients prescribed bupropion in the UK will most commonly be using it as part of a supported smoking cessation programme.

Bupropion works differently from most antidepressants: rather than primarily targeting serotonin, it inhibits the reuptake of dopamine and noradrenaline, making it a noradrenaline–dopamine reuptake inhibitor (NDRI). This distinct mechanism is associated with a somewhat different side-effect profile compared with selective serotonin reuptake inhibitors (SSRIs).

Hair loss — medically termed alopecia — is listed as an adverse effect in bupropion's UK Summary of Product Characteristics (SmPC) for Zyban, as reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA). The precise frequency category should be confirmed in the current UK Zyban SmPC (available via the Electronic Medicines Compendium, emc.medicines.org.uk). There is no firmly established causal mechanism explaining how bupropion might trigger hair loss. One proposed hypothesis involves the drug's influence on dopaminergic pathways, which may indirectly affect the hair growth cycle; however, this remains speculative and is not confirmed in controlled studies.

If bupropion does contribute to hair loss, it is most likely to manifest as telogen effluvium — a diffuse, temporary shedding of hair in which follicles prematurely enter the resting (telogen) phase. This type of hair loss typically presents two to four months after a triggering event and is usually reversible once the cause is addressed. Patients should not discontinue bupropion without first consulting their prescribing clinician, as abrupt cessation carries its own risks, including return of the condition being treated.

Not sure if this is normal? Chat with one of our pharmacists →

How Common Is Hair Loss With Bupropion in Clinical Evidence?

Hair loss is a recognised but uncommon side effect of bupropion; one observational study found a higher relative risk compared with SSRIs, though absolute risk is low and causality is difficult to establish.

Quantifying the true incidence of hair loss associated with bupropion is challenging, largely because robust, large-scale randomised controlled trials have not specifically investigated alopecia as a primary outcome. The frequency of alopecia in the UK Zyban SmPC should be taken as the authoritative reference; patients and clinicians are encouraged to consult the current SmPC via the Electronic Medicines Compendium (emc.medicines.org.uk) for the exact frequency category, as numeric estimates not directly sourced from the SmPC may be unreliable.

A review of case reports and pharmacovigilance databases — including the MHRA's Yellow Card scheme — does include individual reports of hair thinning and shedding in patients taking bupropion. However, causality is difficult to establish in these cases because:

• Many patients take multiple medications simultaneously, any of which could contribute to hair loss.

• Depression, anxiety, and the psychological stress of attempting to stop smoking are themselves associated with telogen effluvium.

• Nutritional deficiencies, thyroid dysfunction, and hormonal changes — all of which can co-exist with the conditions bupropion treats — are well-recognised causes of hair loss.

Importantly, at least one large observational cohort study (Etminan et al., 2018) reported a higher relative risk of hair loss with bupropion compared with several SSRIs and SNRIs. The absolute risk remains low, and observational studies of this type cannot definitively establish causation; nonetheless, this evidence means that bupropion should not be dismissed as a low-risk option in patients with pre-existing hair loss concerns. Overall, while hair loss is a recognised but uncommon possibility with bupropion, it should not be considered a predictable or inevitable consequence of treatment, and the majority of individuals taking bupropion do not experience this side effect.

Other Medications and Conditions That May Affect Hair

Many medications — including anticoagulants, valproate, and beta-blockers — and conditions such as hypothyroidism and iron deficiency are well-established causes of alopecia that must be excluded before attributing hair loss to bupropion.

Before attributing hair loss solely to bupropion, it is clinically important to consider the wide range of other medications and underlying health conditions that are well-established causes of alopecia. This is particularly relevant because patients prescribed bupropion often have complex medical histories and may be taking several treatments concurrently.

Medications commonly associated with hair loss include:

• Anticoagulants such as warfarin and heparin, which are among the most frequently implicated drugs in telogen effluvium.

• Retinoids (e.g., isotretinoin) used in dermatology.

• Antithyroid drugs such as carbimazole.

• Mood stabilisers, particularly valproate (sodium valproate), which has a well-documented association with hair thinning, and lithium.

• Antiepileptics such as topiramate.

• Beta-blockers such as propranolol.

• Hormonal contraceptives, especially those with a higher androgenic profile.

• Chemotherapy agents, which cause anagen effluvium through direct follicular toxicity.

Underlying medical conditions are equally important to consider. Hypothyroidism is one of the most common and treatable causes of diffuse hair loss and should be excluded with a thyroid function test in any patient presenting with new-onset alopecia. Iron deficiency, polycystic ovary syndrome (PCOS), autoimmune conditions such as alopecia areata, and scalp disorders such as seborrhoeic dermatitis can all contribute to hair shedding. Postpartum telogen effluvium and androgenetic alopecia are also important differentials that should be considered in the appropriate clinical context.

Psychological stress — which is inherently linked to the conditions for which bupropion is prescribed — is itself a recognised trigger for telogen effluvium, creating a confounding factor that makes it genuinely difficult to isolate the drug as the sole cause.

Red flags requiring prompt dermatology assessment include: scarring or inflammation of the scalp, rapidly progressive or patchy hair loss, hair loss accompanied by systemic symptoms, or hair loss in a child. These features may indicate conditions requiring urgent specialist evaluation and should not be attributed to medication without further assessment. A thorough clinical assessment, including a detailed medication review and targeted investigations, is therefore essential before concluding that bupropion is responsible for a patient's hair loss.

What to Do If You Notice Hair Loss During Treatment

Contact your GP or prescribing clinician rather than stopping bupropion abruptly; they can arrange targeted investigations, review your medication, and discuss alternatives such as varenicline or nicotine replacement therapy if appropriate.

If you notice increased hair shedding or thinning whilst taking bupropion, the most important first step is to contact your GP or prescribing clinician rather than stopping the medication abruptly. If you are taking bupropion (Zyban) for smoking cessation, stopping suddenly may increase the risk of relapse; if you are taking it off-label for depression under specialist supervision, any changes should be discussed with the initiating specialist. Your clinician will be best placed to assess whether the hair loss is likely to be drug-related or attributable to another cause.

During your consultation, your GP may recommend investigations to rule out other causes. These should be guided by your individual history and clinical examination, and may include:

• Full blood count (FBC) to check for anaemia.

• Serum ferritin and C-reactive protein (CRP) to assess iron stores in context (CRP helps interpret ferritin, which is an acute-phase reactant).

• Thyroid function tests (TFTs), including TSH and free T4.

• Hormonal profile if PCOS or androgen excess is suspected.

• Vitamin D and B12 levels, where there is a clinical indication based on history or examination findings — these are not required routinely in all patients.

If investigations are normal and bupropion remains the most likely cause, your clinician may discuss the option of switching to an alternative treatment, adjusting the dose, or continuing whilst monitoring — particularly if the medication is providing significant therapeutic benefit. For smoking cessation, alternative licensed therapies (such as varenicline or nicotine replacement therapy, as outlined in NICE TA39 and NICE CKS: Smoking Cessation) may be considered. In many reported cases, hair loss associated with bupropion has been self-limiting and reversible upon dose reduction or discontinuation.

For ongoing or significant concerns — particularly if the hair loss is patchy, rapidly progressive, associated with scalp changes, or accompanied by any of the red flags described above — your GP may refer you to an NHS dermatologist (or a GP with an extended role in dermatology) for specialist assessment.

If you believe your hair loss may be related to bupropion or any other medicine, you can report this suspected side effect directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This helps build the national evidence base for drug safety monitoring. Maintaining open communication with your healthcare team remains the safest and most effective approach throughout.

Frequently Asked Questions